Humacyte Inc.
HUMA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HUMA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HUMA
Humacyte Inc. (HUMA) is a biotechnology company developing and commercializing acellular tissue-engineered vessels, with its lead product Symvess approved for vascular trauma and undergoing clinical trials for additional indications.
Key risk: Need for additional capital
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 10 clinical trials · 3 catalysts for Humacyte Inc..
Humacyte Inc. (HUMA) is a biotechnology company developing and commercializing acellular tissue-engineered vessels, with its lead product Symvess approved for vascular trauma and undergoing clinical trials for additional indications.
- Humacyte received FDA approval to commercialize Symvess for the vascular trauma indication [sec_mda · as of 2025-11-12].
- As of June 30, 2025, the company had cash and cash equivalents of $38.0 million and restricted cash of $50.4 million [sec_mda · as of 2025-08-11].
- The company is conducting Phase 3 clinical trials for Symvess in arteriovenous access for hemodialysis and extremity vascular trauma, with topline results expected in 2028 [catalyst_timeline].
- Humacyte plans to initiate a Phase 2a study for a coronary tissue-engineered graft in September 2026 [catalyst_timeline].
- The company has an accumulated deficit and expects to need additional funding to support its development and commercialization activities [sec_mda · as of 2026-08-12].
What works
- Symvess has received FDA approval for vascular trauma, providing a commercial revenue stream [sec_mda · as of 2025-11-12].
- The company has multiple ongoing Phase 3 trials in large markets (hemodialysis access and extremity trauma) with topline data expected in 2028 [catalyst_timeline].
- Humacyte is expanding its pipeline into coronary artery bypass grafting (CABG) and bioengineered vessels for diabetes, with a Phase 2a study planned for 2026 [catalyst_timeline].
What to weigh
- Humacyte has a history of net losses and an accumulated deficit, with a net loss of $36.8M for the six months ended June 30, 2026 [sec].
- The company will need additional funding to support its clinical trials and commercialization, and its future capital requirements are uncertain [sec_mda · as of 2026-08-12].
- Revenue from Symvess is still nascent, and the company has only recently generated revenue from commercial sales [sec_mda · as of 2025-11-12].
- Clinical trial enrollment, results, and regulatory approvals for additional indications are subject to significant risks and uncertainties [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
FDA approval for Symvess commercialization
“We recently received FDA approval to commercialize Symvess and have only recently generated revenue from the sale of commercialize”
SEC MD&A · November 12, 2025
Cash position as of June 30, 2025
“As of June 30, 2025, we had cash and cash equivalents of $38.0 million and restricted cash of $50.4 million.”
SEC MD&A · August 11, 2025
Need for additional funding
“We will need additional funding in connection with these activities.”
SEC MD&A · August 12, 2026
Risks in clinical development
“the scope, rate of progress, expense and results of our preclinical development activities, our ongoing clinical trials and any additional clinical trials that we may conduct, and other research and development activities”
SEC MD&A · May 13, 2026
Catalyst timeline
- 2026-09-01 · Phase 2 Start: A Phase 2a Study for the Evaluation of Safety and Efficacy of Humacyte's Coronary Tissue Engineered — Initiation of a Phase 2a study for a coronary tissue-engineered graft, expanding the pipeline into cardiac surgery.
- 2028-06-01 · Phase 3 Topline: A Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Acellular Tissue Engin — Topline results from a Phase 3 trial comparing Symvess in arteriovenous access for hemodialysis, a key commercial opportunity.
- 2028-12-01 · Phase 3 Topline: A Prospective, Multi-center, Open-label Study, to Assess the Safety and Efficacy of SYMVESS® as a Va — Topline results from a Phase 3 trial evaluating Symvess for extremity vascular trauma, supporting label expansion.
Risks & what to watch (4)›
Key risks
- Need for additional capital — The company will need additional funding to support development and commercialization, and future capital requirements are uncertain [sec_mda · as of 2026-08-12].
- Clinical trial risks — Clinical trials for Symvess in new indications may fail to meet endpoints or face enrollment delays [sec_mda · as of 2026-05-13].
- Limited commercial revenue — Revenue from Symvess is only recently generated and may not be sufficient to cover operating costs [sec_mda · as of 2025-11-12].
- Regulatory approval uncertainty — Marketing approvals for additional indications are subject to FDA review and may not be obtained [sec_mda · as of 2026-05-13].
What to watch
- Initiation of Phase 2a study for coronary tissue-engineered graft in September 2026 [catalyst_timeline].
- Topline results from Phase 3 trial in arteriovenous access for hemodialysis expected in June 2028 [catalyst_timeline].
- Topline results from Phase 3 trial in extremity vascular trauma expected in December 2028 [catalyst_timeline].
- Cash runway and potential need for additional financing as the company scales commercialization and clinical programs [sec_mda · as of 2026-08-12].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Humacyte Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Humacyte Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
11.4 months
D/E 3.42 · 0% dilution
Lead: Approved
3 candidates
3 upcoming, next in ~2d
4 buys · 2 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
158
Total value held
$38.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 14,316,324 | $8.7M |
| blackrock, inc. | 12,316,955 | $7.5M |
| antipodes partners ltd | 5,723,750 | $3.5M |
| great point partners llc | 3,750,000 | $2.3M |
| geode capital management, llc | 3,658,108 | $2.2M |
| state street corp | 3,043,929 | $1.8M |
| aqr capital management llc | 1,924,691 | $1.2M |
| susquehanna international group, llp | 1,757,548 | $1.1M |
| vanguard portfolio management llc | 1,417,825 | $861K |
| charles schwab investment management inc | 1,291,345 | $783K |
Showing top 10 of 158 institutional holders of Humacyte Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 20.9%
- Days to cover
- 4.5
- Shares short
- 42,223,438
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HUMA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Humacyte Inc.?
Humacyte Inc. (HUMA) is a biotechnology company developing and commercializing acellular tissue-engineered vessels, with its lead product Symvess approved for vascular trauma and undergoing clinical trials for additional indications.
What is Humacyte Inc.'s lead drug candidate?
Humacyte Inc.'s most advanced tracked candidate is atev (Phase 4) for Arteriovenous (AV) access for hemodialysis.
What is Humacyte Inc.'s next catalyst?
Humacyte Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2a Study for the Evaluation of Safety and Efficacy of Humacyte's Coronary Tissue Engineered " — expected September 1, 2026.
Who is the CEO of Humacyte Inc.?
Dr. Laura E. Niklason M.D., Ph.D. is the chief executive officer of Humacyte Inc. (HUMA).
Where is Humacyte Inc. headquartered?
Humacyte Inc. (HUMA) is headquartered in Durham, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.